SEP-363856
- Generic Name
- SEP-363856
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13NOS
- CAS Number
- 1310426-33-5
- Unique Ingredient Identifier
- 3K6270MG59
- Background
SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A).
...
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 60
- Registration Number
- NCT05848700
- Locations
- 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States
🇺🇸Pillar Clinical Research, LLC, Richardson, Texas, United States
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05741528
- Locations
- 🇺🇸
Advanced Research Center Inc., Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸Clinical Innovations, Inc., Riverside, California, United States
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 434
- Registration Number
- NCT05729373
- Locations
- 🇪🇸
Hospital de Antequera Site#400, Málaga, Spain
🇺🇸University of Alabama at Birmingham Site #116, Huntsville, Alabama, United States
🇺🇸Excell Research, Inc. Site #106, Oceanside, California, United States
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 101
- Registration Number
- NCT05628103
- Locations
- 🇺🇸
Clinical Innovations, Inc, Riverside, California, United States
🇺🇸California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego, California, United States
🇺🇸Cenexel CNS Research, Torrance, California, United States
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-05-29
- Target Recruit Count
- 900
- Registration Number
- NCT05593029
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 19
- Registration Number
- NCT05542264
- Locations
- 🇺🇸
Shari DeSilva, Rogers, Arkansas, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 15
- Registration Number
- NCT05463770
- Locations
- 🇺🇸
CNRI - San Diego LLC, San Diego, California, United States
🇺🇸Catalina Research Institute LLC, Montclair, California, United States
🇺🇸Pillar Clinical Research, LLC, Richardson, Texas, United States
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 31
- Registration Number
- NCT05402111
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Research, LLC, Long Beach, California, United States
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05359081
- Locations
- 🇯🇵
Sangubashi Kokorono Clinic, Shibuya-ku, Tokyo, Japan
🇯🇵Ryokuwakai Stresscare Hibiya Clinic, Chiyoda-ku, Tokyo, Japan
🇯🇵Kuramitsu Hospital, Fukuoka-shi, Fukuoka, Japan
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 21
- Registration Number
- NCT04865835
- Locations
- 🇺🇸
Hassman Research Institute, Marlton, New Jersey, United States
🇺🇸At Fort Lauderdale Behavioral Health Center, Oakland Park, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.